Advancing Gender Equity in Urology: Allyship for Men and Advocacy for Women Webcast (2023)
There is a lack of widespread awareness of how gender bias or sexism affects women in the urological workplace, and while primarily women are contributing to the scientific literature that examines these issues, its dissemination to those in leadership or in charge of policy can be limited. Addressing this requires both advocacy from women and allyship from men to promote fair and equitable work environments. The course will define, based on the evidence and data, the current state of women in urology and, through a series of case presentations, will identify the challenges women face across the career trajectory as students (selecting surgery and urology, match rates, letters of recommendation, interviews), residents (implicit bias and operative autonomy) and attendings (practice patterns, work-life integration, promotions, salary equity). Strategies of action to address gender bias and sexism will be reviewed including allyship, sponsorship, trust and reciprocity, disrupting bias and sexism, and advocacy. Audience participation will be facilitated through course director Q&A on the floor.
Independent educational grant support provided by:
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Merck & Co., Inc.
At the conclusion of this activity, participants will be able to:
- Recognize how gender bias operates in medicine and urology specifically in terms of career success and advancement as well as ability to care for patients and work within health care systems at the individual and institutional levels.
- Identify and mitigate macro- and microaggressions in the workplace by practicing techniques to interrupt, validate and be an active bystander/ally.
- Recognize intersectionality issues in gender equity.
- Develop strategies for allyship and advocacy and practice.
- Develop core competencies for both women and men to enact change in their sphere of influence on salary and compensation equity, personal and family leave practices, administrative structuring, workplace safety and speaking up, and promotion and advancement.
|Name||Company Name||Relationship Type||End Date|
|Sam S. Chang, MD, MBA||GLG||Consultant or Advisor||Current|
|Virtuoso surgical||Consultant or Advisor||Current|
|Prokarium||Consultant or Advisor||Current|
|Tu Therapeutics||Consultant or Advisor||Current|
|Janssen||Consultant or Advisor||Current|
|BMS||Consultant or Advisor||01/01/2022|
|pfizer||Consultant or Advisor||Current|
|urogen||Consultant or Advisor||Current|
|mIR||Consultant or Advisor||Current|
|Lantheus||Consultant or Advisor||Current|
|Merck||Consultant or Advisor||Current|
|Pacific Edge||Consultant or Advisor||Current|
|Nonagen||Consultant or Advisor||Current|
|Astra zeneca||Consultant or Advisor||Current|
|Mathew Don Sorensen, MD, MS, FACS||Sonomotion, inc||Consultant or Advisor||Current|
|Microline||Consultant or Advisor||6/30/2022|
|Akanksha Mehta, MD||None|
|Maria Uloko, MD||Non|
|Simone Thavaseelan, MD||None|
EDUCATION COUNCIL DISCLOSURES:
COI REVIEW WORKGROUP DISCLOSURES:
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by view the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
Estimated time to complete this activity: 2.00 hours
Release Date: May, 2023
Expiration Date: May, 2024
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:
- Peer review for valid, evidence-based content by the AUA COI Review Work Group.
- Attestation that clinical recommendations are evidence-based and free of commercial bias.
- Introduction of a debate format (point-counterpoint)
- Inclusion of moderated panel discussion with unbiased moderator
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Divestiture of the relationship by faculty
- Recusal from controlling relevant aspects of planning
- Selection of alternative faculty for specific topic
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation